Composition for preventing or treating side effect of steroid in subject comprising acetylsalicylic acid and use thereof
A method for preventing or treating side effects of glucocorticoid in a subject including administrating to a subject acetylsalicylic acid a pharmaceutically acceptable salt, solvate, or polymorph thereof, or a combination of at least two of the foregoing.
1. A method of treating a side effect of glucocorticoid treatment or other increase in glucocorticoid levels in a subject afflicted with such side effects, the method comprising administering acetylsalicylic acid or a pharmaceutically acceptable salt thereof to the subject.
2. The method of claim 1 , wherein the side effect of glucocorticoid treatment is muscular atrophy, decreased muscle function, muscular pain, arthritic pain, impaired glucose tolerance, loss of appetite, body weight loss, decreased bone metabolism, impaired immunity, nephrotic syndrome, fatigability, or combination thereof.
3. The method of claim 1 , wherein the side effect of glucocorticoid treatment is caused by an increase in Atrogin-1 activity, an increase in MuRF-1 activity, or a combination thereof.
4. The method of claim 1 , wherein Atrogin-1 activity, MuRF-1 activity, phosphorylation of a glucocorticoid receptor (GR), or combination thereof is reduced in a subject by the administering of the acetylsalicylic acid.
5. The method of claim 1 , wherein the at least one glucocorticoid comprises at least one selected from the group consisting of cortisol, hydrocortine, cortisone, prednisolone, methylprednisolone, triamcinolone, triamcinolone acetonide, paramethasone, dexamethasone, betamethasone, hexestrol, methimazole, fluocinonide, fluocinolone acetonide, fluorometholon, beclomethasone dipropionate, estriol, diflorasone diacetate, diflucortolone valerate, and difluprednate.
6. The method of claim 1 , wherein the acetylsalicylic acid or pharmaceutically acceptable salt thereof, is administered in a dose in a range of about 0.001 mg/kg to about 100 mg/kg.
7. The method of claim 1 , wherein the acetylsalicylic acid or pharmaceutically acceptable salt thereof is administered via oral, intravenous, intramuscular, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration.
8. The method of claim 1 , wherein the acetylsalicylic acid or pharmaceutically acceptable salt thereof is administered once a day, multiple times a day, or once every three days.
9. A method for reducing Atrogin-1 or MuRF-1 activity levels in a subject treated with at least one glucocorticoid, comprising administering acetylsalicylic acid or a pharmaceutically acceptable salt thereof to the subject, wherein the Atrogin-1 and MuRF-1 activity levels are reduced in comparison to the activity levels in a control subject.
10. A method for reducing phosphorylation of the Glucocorticoid Receptor (GR) in a subject treated with at least one glucocorticoid, comprising administering acetylsalicylic acid or a pharmaceutically acceptable salt thereof to the subject, wherein the phosphorylation level of GR is reduced in comparison to the phosphorylation levels of GR in a control subject.
11. The method of claim 1 , wherein the acetylsalicylic acid is administered via oral, intravenous, intramuscular, or subcutaneous administration.
12. The method of claim 1 , wherein the acetylsalicylic acid is administered via the oral route in the form of a tablet consisting essentially of acetylsalicylic acid.
13. A method of glucocorticoid treatment with reduced side effects, the method consisting of administering to a subject in need of glucocorticoid treatment a glucocorticoid and acetylsalicylic acid or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein the glucocorticoid and acetylsalicylic acid are administered as a single composition.